PLUS1
67.41
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd | BHVN | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 1.13 | 1.7% | 67.41 | 65.372 | 69.36 | 65.69 | 66.28 | 16:00:04 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,139 | 961,033 | $ 67.43 | $ 64,803,853 | 805,541 | 26.56 - 69.36 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:49:57 | formt | 136 | $ 67.41 | USD |
Biohaven Pharmaceutical Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.95B | 58.53M | 53.07M | $ - | $ - | -10.99 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 10.57M | $ - | 0.00% | - | - |
Biohaven Pharmaceutical News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/02/2020 | 09:04 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/19/2020 | 16:34 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/18/2020 | 07:30 | PR Newswire (US) | Biohaven Showcases Clinical and Pharmacoeconomic Data for.. |
| 5/07/2020 | 17:20 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/07/2020 | 17:11 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/07/2020 | 16:10 | PR Newswire (US) | Biohaven Pharmaceuticals Reports First Quarter 2020.. |
| 4/30/2020 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BHVN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 60.43 | 69.36 | 57.11 | 64.03 | 795,497 | 6.98 | 11.55% |
| 1 Month | 49.52 | 69.36 | 42.74 | 55.52 | 786,890 | 17.89 | 36.13% |
| 3 Months | 36.82 | 69.36 | 26.56 | 41.33 | 949,717 | 30.59 | 83.08% |
| 6 Months | 53.92 | 69.36 | 26.56 | 45.98 | 938,884 | 13.49 | 25.02% |
| 1 Year | 56.11 | 69.36 | 26.56 | 45.54 | 887,946 | 11.30 | 20.14% |
| 3 Years | 24.56 | 69.36 | 16.5001 | 41.47 | 558,541 | 42.85 | 174.47% |
| 5 Years | 20.00 | 69.36 | 16.5001 | 41.03 | 555,080 | 47.41 | 237.05% |
Biohaven Pharmaceutical Description
| Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others. |
